# Antimicrobial Prophylaxis per CD4 Counts 

Rachel Pellegrino

---

<table border="1">
  <tr>
    <th>CD4 counts</th>
    <th>Opportunistic Infection</th>
    <th>Indication for Prophylaxis</th>
    <th>Medication</th>
    <th>Special Notes</th>
  </tr>
  <tr>
    <td>&lt;200 cells/mm3</td>
    <td>Pneumocystis Pneumonia (PJP)</td>
    <td>CD4 &lt; 200, or CD4 &lt; 14%, may consider discontinuation if CD4 100-200 in setting of viral suppression</td>
    <td>TMP-SMX: 1 DS daily (qd), or TMP-SMX: 1SS qd TMP-SMX: 1 DS TIW</td>
    <td>If intolerant of TMP-SMX: dapsone*, or inhaled pentamidine, or atovaquone</td>
  </tr>
  <tr>
    <td>&lt;200 cells/mm3</td>
    <td>Toxoplasma gondii encephalitis</td>
    <td>Toxoplasma IgG + and CD4 &lt; 100</td>
    <td>TMP-SMX 1 DS tab daily</td>
    <td>Alternative regimens: dapsone + pyrimethamine + leucovorin, or atovaquone (all regimens also effective for PJP)</td>
  </tr>
  <tr>
    <td>&lt;50 cells/mm3</td>
    <td>Mycobacterium avium-intracellulare (MAC, MAI)</td>
    <td>Only if not on fully suppressive ART and active disseminated MAC is ruled out</td>
    <td>Azithromycin 1200 mg weekly, or Clarithromycin 500 mg BID, or Rifabutin 300 mg daily</td>
    <td>NOT indicated for those initiating ART</td>
  </tr>
</table>

<table border="1">
  <tr>
    <th>Infection</th>
    <th>Screening Indication</th>
    <th>Prevention or Intervention</th>
  </tr>
  <tr>
    <td>Hepatitis A Virus (HAV)</td>
    <td>Non-immune with â†‘ risk for HAV infection (MSM, IVDU) or chronic liver disease</td>
    <td>HAV vaccine series</td>
  </tr>
  <tr>
    <td>Hepatitis B Virus (HBV)</td>
    <td>Pts without chronic HBV or non-immune</td>
    <td>HBV vaccine series</td>
  </tr>
  <tr>
    <td>Human Papilloma virus (HPV)</td>
    <td>Age 13-45</td>
    <td>HPV vaccine series</td>
  </tr>
  <tr>
    <td>Influenza A and B Virus</td>
    <td>All pts</td>
    <td>Yearly inactivated influenza vaccine</td>
  </tr>
  <tr>
    <td>Latent Mycobacterium tuberculosis infection (LTBI)</td>
    <td>Pts with positive screening test for LTBI with no evidence of active disease.<br>Pts with known exposure</td>
    <td>(INH 300mg + pyridoxine 25-50mg) PO daily for 9 months</td>
  </tr>
  <tr>
    <td>Streptococcus pneumoniae</td>
    <td>All pts</td>
    <td>Pts without any previous pneumococcal vaccines: Give PCV15 or PCV20. If PCV15 is used, also give PPSV23 in 1 year.<br><br>Pts who have already received PPSV23: Give PCV15 or PCV20 one year after most recent PPSV23 vaccine<br><br>Pts who have already received PCV13: Give PPSV23</td>
  </tr>
  <tr>
    <td>Syphilis</td>
    <td>All sexually active pts</td>
    <td>Screening for syphilis and gonorrhea/chlamydia with treatment if indicated.</td>
  </tr>
  <tr>
    <td>Herpes zoster (shingles)</td>
    <td>Pts &gt; age 50</td>
    <td>Shingrix (recombinant zoster) vaccine series</td>
  </tr>
</table>

